Guidance for Anika Therapeutics Inc. (ANIK)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $114.00M – 122.50M | $117.20M | = Maintained | Details |
| 2026 | N/A | N/A | $114.00M – 122.50M | $116.40M | = Maintained | Details |
| 2024 | N/A | N/A | $168.00M – 173.00M | $170.80M | = Maintained | Details |
| 2024 | N/A | N/A | $168.00M – 173.00M | $170.30M | = Maintained | Details |
| Q1 2024 | N/A | N/A | $168.00M – 173.00M | $179.40M | = Maintained | Details |
| 2023 | N/A | N/A | $159.50M – 163.00M | $161.90M | = Maintained | Details |
| Q3 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
